- Home
- RENX vs VRAX Comparison
RENX vs VRAX Comparison
Compare RENX & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RENX | VRAX |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 1.7M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | RENX | VRAX |
|---|---|---|
| Price | $0.22 | $0.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | ★ 4.0M | 199.5K |
| Earning Date | 03-31-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,970,752.00 | $2,986.00 |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2770.15 | N/A |
| 52 Week Low | $0.11 | $0.22 |
| 52 Week High | $2.36 | $2.10 |
Technical Indicators
Market Signals| Indicator | RENX | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 60.95 | 30.83 |
| Support Level | $0.13 | $0.22 |
| Resistance Level | $0.16 | $0.26 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 45.85 | 13.00 |
Price Performance
Historical ComparisonAbout RENX RenX Enterprises Corp. Common Stock
RenX Enterprises Corp is a real estate development and environmental solutions company. It is focused on the direct acquisition and indirect investment in properties across the United States that are intended for development into green single-family or multifamily housing projects. The company also focuses on the monetization of its real estate assets. It processes source-separated green waste and is expanding into the production of sustainable, high-margin potting media and soil substrates through advanced milling technology.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.